1. Home
  2. SXTC vs PFSA Comparison

SXTC vs PFSA Comparison

Compare SXTC & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo China SXT Pharmaceuticals Inc.

SXTC

China SXT Pharmaceuticals Inc.

N/A

Current Price

$1.44

Market Cap

1.8M

Sector

Health Care

ML Signal

N/A

PFSA

Profusa Inc.

HOLD

Current Price

$0.27

Market Cap

1.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SXTC
PFSA
Founded
2005
2009
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8M
1.7M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
SXTC
PFSA
Price
$1.44
$0.27
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
27.1K
167.6K
Earning Date
08-19-2019
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.03
$0.05
52 Week High
$6.98
$4.22

Technical Indicators

Market Signals
Indicator
SXTC
PFSA
Relative Strength Index (RSI) 38.02 27.37
Support Level $1.37 $0.07
Resistance Level $1.51 $0.41
Average True Range (ATR) 0.12 0.03
MACD 0.01 0.00
Stochastic Oscillator 15.89 4.91

Price Performance

Historical Comparison
SXTC
PFSA

About SXTC China SXT Pharmaceuticals Inc.

China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.

About PFSA Profusa Inc.

Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.

Share on Social Networks: